Treatment Options for Patients with Inflammatory Bowel Disease During the COVID-19 Epidemic: A Review
Author(s):
Zhao Peng, Na Wu, Rui Wang, Duo Li
The Corona Virus Disease (COVID-19) outbreak is affecting life around the world. In particular, people with basic diseases are concerned about whether COVID-19 will affect their original disease,Increasing attention is whether patients with inflammatory bowel disease (IBD) are more susceptible to COVID-19.Whether the treatment plans need to be adjusted, Summary literature shows that IBD patients have comparable infection rates as those in the general population, patients with IBD using biologics are more likely to develop asymptomatic infections and have fewer symptoms than normal populations, The use of parenteral-selective biologic agents may have a protective effect in lung function, which may be associated with its mitigation of cytokine storm syndrome. So patients with IBD should not interrupt the original biological treatment regimen. However, in preparation selection, parenteral-selective biological agents are preferred.